BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23594232)

  • 1. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
    APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.
    Andersson E; Villabona L; Bergfeldt K; Carlson JW; Ferrone S; Kiessling R; Seliger B; Masucci GV
    Cancer Immunol Immunother; 2012 Aug; 61(8):1243-53. PubMed ID: 22258792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
    Köbel M; Madore J; Ramus SJ; Clarke BA; Pharoah PD; Deen S; Bowtell DD; Odunsi K; Menon U; Morrison C; Lele S; Bshara W; Sucheston L; Beckmann MW; Hein A; Thiel FC; Hartmann A; Wachter DL; Anglesio MS; Høgdall E; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Fogarty ZC; Vierkant RA; Liu S; Cho S; Nelson G; Ghatage P; Gentry-Maharaj A; Gayther SA; Benjamin E; Widschwendter M; Intermaggio MP; Rosen B; Bernardini MQ; Mackay H; Oza A; Shaw P; Jimenez-Linan M; Driver KE; Alsop J; Mack M; Koziak JM; Steed H; Ewanowich C; DeFazio A; Chenevix-Trench G; Fereday S; Gao B; Johnatty SE; George J; Galletta L; ; Goode EL; Kjær SK; Huntsman DG; Fasching PA; Moysich KB; Brenton JD; Kelemen LE
    Br J Cancer; 2014 Dec; 111(12):2297-307. PubMed ID: 25349970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular markers for predicting prostate cancer stage and survival.
    Dunsmuir WD; Gillett CE; Meyer LC; Young MP; Corbishley C; Eeles RA; Kirby RS
    BJU Int; 2000 Nov; 86(7):869-78. PubMed ID: 11069416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients.
    Korkolopoulou P; Vassilopoulos I; Konstantinidou AE; Zorzos H; Patsouris E; Agapitos E; Davaris P
    Gynecol Oncol; 2002 Jun; 85(3):404-14. PubMed ID: 12051866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of preoperative KISS1 gene in tumor tissue with epithelial ovarian cancer and its prognostic value.
    Cao F; Chen L; Liu M; Lin W; Ji J; You J; Qiao F; Liu H
    Medicine (Baltimore); 2016 Nov; 95(46):e5296. PubMed ID: 27861355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis.
    Layfield LJ; Saria EA; Berchuck A; Dodge RK; Thompson JK; Conlon DH; Kerns BJ
    J Surg Oncol; 1997 Dec; 66(4):230-6; discussion 236-7. PubMed ID: 9425325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.
    Martins FC; Couturier DL; Paterson A; Karnezis AN; Chow C; Nazeran TM; Odunsi A; Gentry-Maharaj A; Vrvilo A; Hein A; Talhouk A; Osorio A; Hartkopf AD; Brooks-Wilson A; DeFazio A; Fischer A; Hartmann A; Hernandez BY; McCauley BM; Karpinskyj C; de Sousa CB; Høgdall C; Tiezzi DG; Herpel E; Taran FA; Modugno F; Keeney G; Nelson G; Steed H; Song H; Luk H; Benitez J; Alsop J; Koziak JM; Lester J; Rothstein JH; de Andrade JM; Lundvall L; Paz-Ares L; Robles-Díaz L; Wilkens LR; Garcia MJ; Intermaggio MP; Alcaraz ML; Brett MA; Beckmann MW; Jimenez-Linan M; Anglesio M; Carney ME; Schneider M; Traficante N; Pejovic N; Singh N; Le N; Sinn P; Ghatage P; Erber R; Edwards R; Vierkant R; Ness RB; Leung S; Orsulic S; Brucker SY; Kaufmann SH; Fereday S; Gayther S; Winham SJ; Kommoss S; Pejovic T; Longacre TA; McGuire V; Rhenius V; Sieh W; Shvetsov YB; Whittemore AS; Staebler A; Karlan BY; Rodriguez-Antona C; Bowtell DD; Goode EL; Høgdall E; Candido Dos Reis FJ; Gronwald J; Chang-Claude J; Moysich KB; Kelemen LE; Cook LS; Goodman MT; Fasching PA; Crawford R; Deen S; Menon U; Huntsman DG; Köbel M; Ramus SJ; Pharoah PDP; Brenton JD
    Br J Cancer; 2020 Sep; 123(5):793-802. PubMed ID: 32555365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki 67 expression in 35 borderline ovarian tumours: relations with clinicopathologic parameters and ploidy.
    Darai E; Walker-Combrouze F; Dauge-Geoffroy MC; Vincent Y; Feldmann G; Madelenat P; Scoazec JY
    Eur J Obstet Gynecol Reprod Biol; 1998 Feb; 76(2):175-80. PubMed ID: 9481570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions.
    Wang Y; Wang Y; Wei L; Hong S; Zhao M; Zhang X; Zheng W
    J Ovarian Res; 2017 Mar; 10(1):12. PubMed ID: 28270171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases.
    Ariyoshi K; Kawauchi S; Kaku T; Nakano H; Tsuneyoshi M
    Histopathology; 2000 Nov; 37(5):427-36. PubMed ID: 11119124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors.
    Beeghly-Fadiel A; Wilson AJ; Keene S; El Ramahi M; Xu S; Marnett LJ; Fadare O; Crispens MA; Khabele D
    J Ovarian Res; 2018 Feb; 11(1):17. PubMed ID: 29482584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records.
    Lim A; Mesher D; Gentry-Maharaj A; Balogun N; Widschwendter M; Jacobs I; Sasieni P; Menon U
    BJOG; 2016 May; 123(6):1012-20. PubMed ID: 26032603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas.
    Jansson A; Sun XF
    APMIS; 1997 Sep; 105(9):730-4. PubMed ID: 9350218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma.
    Skirnisdóttir I; Sorbe B; Seidal T
    Int J Gynecol Cancer; 2001; 11(2):119-29. PubMed ID: 11328410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer.
    Block MS; Charbonneau B; Vierkant RA; Fogarty Z; Bamlet WR; Pharoah PD; ; ; ; Rossing MA; Cramer D; Pearce CL; Schildkraut J; Menon U; Kjaer SK; Levine DA; Gronwald J; Culver HA; Whittemore AS; Karlan BY; Lambrechts D; Wentzensen N; Kupryjanczyk J; Chang-Claude J; Bandera EV; Hogdall E; Heitz F; Kaye SB; Fasching PA; Campbell I; Goodman MT; Pejovic T; Bean YT; Hays LE; Lurie G; Eccles D; Hein A; Beckmann MW; Ekici AB; Paul J; Brown R; Flanagan JM; Harter P; du Bois A; Schwaab I; Hogdall CK; Lundvall L; Olson SH; Orlow I; Paddock LE; Rudolph A; Eilber U; Dansonka-Mieszkowska A; Rzepecka IK; Ziolkowska-Seta I; Brinton LA; Yang H; Garcia-Closas M; Despierre E; Lambrechts S; Vergote I; Walsh CS; Lester J; Sieh W; McGuire V; Rothstein JH; Ziogas A; Lubiński J; Cybulski C; Menkiszak J; Jensen A; Gayther SA; Ramus SJ; Gentry-Maharaj A; Berchuck A; Wu AH; Pike MC; Van Den Berg D; Terry KL; Vitonis AF; Ramirez SM; Rider DN; Knutson KL; Sellers TA; Phelan CM; Doherty JA; Johnatty SE; deFazio A; Song H; Tyrer J; Kalli KR; Fridley BL; Cunningham JM; Goode EL
    Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1421-7. PubMed ID: 24740199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis.
    Kerns BJ; Jordan PA; Faerman LL; Berchuck A; Bast RC; Layfield LJ
    Am J Clin Pathol; 1994 Feb; 101(2):192-7. PubMed ID: 8116574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas.
    Hsu DW; Louis DN; Efird JT; Hedley-Whyte ET
    J Neuropathol Exp Neurol; 1997 Aug; 56(8):857-65. PubMed ID: 9258255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of borderline and invasive mucinous ovarian tumors using Ki-67 (MIB 1) antibodies and nucleolar organizer region (NOR) staining.
    Terlikowski S; Sulkowski S; Lenczewski A; Musiatowicz B; Kulikowski M
    Arch Gynecol Obstet; 1999 Nov; 263(1-2):29-33. PubMed ID: 10728625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benign ovarian tumours.
    Athanassiadou P; Petrakakou E; Sakelariou V; Zerva C; Liossi A; Michalas S; Athanassiades P
    Eur J Cancer Prev; 1998 Jun; 7(3):225-31. PubMed ID: 9696931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.